Latest Breaking News On - Patients with unresectable or metastatic her2 low breast cancer - Page 1 : comparemela.com

Shanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.

Memorial sloan kettering cancer centerShanu modiTrastuzumab deruxtecan in patients with her2 low breast cancerPatients with unresectable or metastatic her2 low breast cancerDestiny breast04 trialPatients with hormone receptor positiveHer2 low metastatic breast cancer